Dynavax Technologies | DVAX - Interest Expense On Debt


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Dynavax Technologies

Dynavax Technologies reported $1.68M in Interest Expense on Debt for its fiscal quarter ending in December of 2022.


Interest Expense On Debt Change
Amgen AMGN:US USD 543M 128M
Biogen BIIB:US USD 62.5M 7.7M
BioMarin Pharmaceutical BMRN:US USD 3.7M 77K
Bristol-Myers Squibb BMY:US USD 288M 6M
Gilead Sciences GILD:US USD 230M 3M
Nektar Therapeutics NKTR:US USD 6.4M 796K
Neurocrine Biosciences NBIX:US USD 1.1M 0
Novartis NOVN:VX USD 211M 8M
Pfizer PFE:US USD 318M 5M
Regeneron Pharmaceuticals REGN:US USD 18M 600K
Roche Holding ROG:VX 348M 92M
Sarepta Therapeutics SRPT:US USD 6.32M 365K
TG Therapeutics TGTX:US USD 2.84M 18K
Vertex Pharmaceuticals VRTX:US USD 11.4M 200K